Enrique Leal - Laboratorios Farmaceuticos Vice Chairman of the Board, Independent Director
| ROVI Stock | EUR 61.85 0.15 0.24% |
Chairman
Mr. Enrique Castellon Leal serves as Independent Director of Laboratorios Farmaceuticos Rovi, S.A. He also acted as Lead Director at the Company until 2016. He joined the Company Board on October 24, 2007. He also acts as Chairman of the Nominating and Remuneration Committee and Member of the Audit Committee of the Company. In the past, he worked at Hospital Clinico San Carlos. In addition, he was Member of Cuerpo de Inspectores Medicos de la Seguridad Social, Managing Director of Servicio Gallego de Salud, Vice Counsel of Sanidad y Servicios Sociales de la Comunidad de Madrid. He has served as Adviser at the law firm Castellon Abogados and Banco Interamericano de Desarollo. He is Founding Partner and Chairman of the Board of Directors of CrossRoadBiotech, as well as he acts as Member of the Board of Directors of CRB SL, Genomadrid SL, Owl Genomics SL, Dendrico SL, One Way Liver Genomics SL, Translational Cancer Drugs Pharma SL and Biocross SL. In addition, he is President of Cross Roard Biotech SA and Cross Road Biotech Inversiones Biotecnologicas SGECR SA, CEO of Genomadrid SL and Dendrico SL. He graduated in Medicine and Surgery from Universidad Complutense de Madrid and holds a degree in Economics and Business Administration from Universidad Autonoma de Madrid and Masters degrees in Public Health, Health Care Policy and Health Systems Management from the Harvard University. since 2016.
| Tenure | 8 years |
| Phone | 34 91 021 30 00 |
| Web | https://www.rovi.es |
Laboratorios Farmaceuticos Management Efficiency
The company has return on total asset (ROA) of 0.1844 % which means that it generated a profit of $0.1844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3919 %, meaning that it generated $0.3919 on every $100 dollars invested by stockholders. Laboratorios Farmaceuticos' management efficiency ratios could be used to measure how well Laboratorios Farmaceuticos manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | CHAIRMAN Age | ||
| Jorge Ballart | Almirall SA | N/A | |
| Thomas McKillop | Almirall SA | 76 | |
Management Performance
| Return On Equity | 0.39 | |||
| Return On Asset | 0.18 |
Laboratorios Farmaceuticos Leadership Team
Elected by the shareholders, the Laboratorios Farmaceuticos' board of directors comprises two types of representatives: Laboratorios Farmaceuticos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratorios. The board's role is to monitor Laboratorios Farmaceuticos' management team and ensure that shareholders' interests are well served. Laboratorios Farmaceuticos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratorios Farmaceuticos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Beatriz Alcalde, Sales Manager Line B | ||
| Ignacio Toledano, Deputy Sec | ||
| Gabriel Fernandez, Non-member Secretary | ||
| Fernando Morales, Commercial Director | ||
| Miguel Freese, Independent Director | ||
| Enrique Leal, Vice Chairman of the Board, Independent Director | ||
| Rosario Prez, Marketing Mang | ||
| Ivan Encina, First Vice Chairman of the Board, Executive Director of Corporate Development | ||
| Jose MorenoBarreda, Independent Director | ||
| Miguel Sanchez, Industrial Director | ||
| Francisco Garca, HR Mang | ||
| Miguel Roman, Director of International Affairs and Development | ||
| Pedro Trillo, Director of Hospital Network | ||
| Marcos Pinto, Lead Independent Director | ||
| Fernando Garijo, Sales Effectiveness Manager | ||
| Mercedes Sanchez, Manager - Legal Department | ||
| Francisco Garcia, Director of Human Resources | ||
| Juan Lopez, Co-CEO, Chairman of the Board, Executive Director | ||
| Javier Encina, Second Vice Chairman of the Board, Chief Financial Officer, Executive Director | ||
| Fatima Garcia, Independent Director | ||
| Pablo Jorge, Chief Economic and Administrative Officer | ||
| M Perez, Marketing Manager | ||
| Juan Encina, Co-CEO, General Director, Executive Director | ||
| Ibon Aduriz, Director of Preclinical Research | ||
| Mercedes Snchez, Legal Mang |
Laboratorios Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratorios Farmaceuticos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.39 | |||
| Return On Asset | 0.18 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 1.93 B | |||
| Shares Outstanding | 51.32 M | |||
| Shares Owned By Insiders | 60.25 % | |||
| Shares Owned By Institutions | 17.88 % | |||
| Price To Earning | 43.87 X | |||
| Price To Book | 4.42 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Laboratorios Stock
Laboratorios Farmaceuticos financial ratios help investors to determine whether Laboratorios Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Laboratorios with respect to the benefits of owning Laboratorios Farmaceuticos security.